利用CRISPR/Cas9对2型血管性血友病中致病性VWF变异进行等位基因选择性破坏
该研究针对由杂合显性负性VWF变异导致的血管性血友病(VWD),开发了一种基因治疗策略:通过Cas9引入插入缺失,选择性破坏致病等位基因的开放阅读框,从而永久失活VWF变异。研究靶向VWF中常见的单核苷酸多态性(SNP)rs1800378,利用携带杂合p.C1190R和p.R1306W变异的VWD2A和VWD2B患者的内皮集落形成细胞(ECFC)进行体外原理验证。下一代测序显示高效且等位基因选择性的VWF敲除,同时维持非靶向等位基因的VWF表达;变异映射质谱证实变异等位基因表达的选择性降低,并伴随ECFC细胞疾病表型的逆转。研究表明,这种新型基因编辑策略具有可行性,且因靶向常见SNP,可广泛适用,不受致病变异、致病机制或VWD亚型限制。
要点
- 靶向VWF常见SNP rs1800378,实现等位基因选择性敲除致病VWF变异。
- 在VWD2A和VWD2B患者ECFC中验证了体外原理,逆转细胞疾病表型。
- 该策略不受致病变异、机制或VWD亚型限制,具有广泛适用性。
核心结论
- 该研究展示了针对VWD的新型基因编辑策略的可行性,通过靶向常见SNP,可广泛适用,不受致病变异、致病机制或VWD亚型限制。
研究设计与样本
- 研究利用携带杂合p.C1190R和p.R1306W变异的VWD2A和VWD2B患者的内皮集落形成细胞(ECFC)进行体外原理验证。
主要发现
- 下一代测序分析显示高效且等位基因选择性的VWF敲除,同时维持非靶向等位基因的VWF表达。
- 变异映射质谱证实变异等位基因表达的选择性降低,并伴随ECFC细胞疾病表型的逆转。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In contrast to major innovations in treating severe hemophilia, the treatment of severe von Willebrand disease (VWD) remains limited to intravenous infusion of von Willebrand factor (VWF) concentrates. To date, no gene therapy-based approaches for the treatment of VWD have been developed, largely owing to the disease's heterogeneous mutational landscape and the challenge of specifically targeting VWF production in endothelial cells. In this study, we developed a novel gene therapy strategy for patients with VWD caused by heterozygous dominant-negative VWF variants. Our strategy permanently inactivates VWF variants by selectively disrupting the pathogenic allele's open reading frame via the introduction of indels by Cas9. To circumvent the challenge of designing variant-specific strategies, we targeted the common single nucleotide polymorphism (SNP) rs1800378 in VWF. We used endothelial colony-forming cells (ECFCs) from patients with VWD2A and VWD2B with heterozygous p.C1190R and p.R1306W variants, respectively, to demonstrate ex vivo proof of principle. Using next-generation sequencing analysis, we show efficient and allele-selective knockout of VWF, while maintaining VWF expression of the nontargeted allele. Variant mapping mass spectrometry that discriminates between wild-type and variant VWF proteoforms confirmed selective reduction of variant allele expression, which was accompanied by reversal of cellular disease phenotypes in ECFCs. This study shows the feasibility of a novel gene editing strategy for VWD that, by virtue of its targeting of a common SNP, can be broadly applicable and can be used to design treatments for VWD without being constrained by the disease-causing variant, pathogenic mechanism, or VWD subtype.
引用
- Bär I, Groten SA, Barraclough A, et al. Allele-selective disruption of pathogenic VWF variants in type 2 von Willebrand disease using CRISPR/Cas9. Blood Adv. 2026. PMID: 41411488. doi:10.1182/bloodadvances.2025018760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。